Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Transpl Int. 2019 Feb 8;32(5):502–515. doi: 10.1111/tri.13395

Figure 3. Death-censored allograft survival was decreased if there was prior history patient induced medication nonadherence or viral infection leading to immunosuppressive reduction.

Figure 3.

Death-censored allograft survival following dnDSA was 70.0% (21/30) in the medication nonadherence group, 67.4% (23/34) in the prior viral infection group, and higher at 87.8%(43/49) in the group with neither medication nonadherence nor prior viral infection during a mean follow-up of 2.2 (IQR 1.2–3.7) years post-dnDSA detection, p=0.009.